pharmaphorum6d
ESMO: Pfizer drug helps cancer patients gain weight
Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...
Pfizer’s Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...
Hold Recommendation on Pfizer Amid Promising but Early Stage Cancer Cachexia Drug Development
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 21. David Risinger ...
BioSpace10d
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...
The Motley Fool8d
3 Factors That Make Pfizer's Ultra-High-Yield Dividend Safer Than You Might Think
Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...
Pfizer, Inc. (PFE) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...
ABC News10d
Pfizer rides Paxlovid sales growth to better-than-expected third quarter
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year A boost from COVID-19 treatment sales helped bush Pfizer to a ...
The Motley Fool23d
Why I'm Considering Leaning Heavily Into Pfizer
Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...
The Day25d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Pfizer won the gratitude of governments and patients alike with the vaccine and its antiviral treatment, Paxlovid. CNN named Bourla CEO of the year in 2021, beating out Alphabet’s Sundar Pichai ...
Investing11d
Pfizer's SWOT analysis: stock outlook amid pipeline progress, cost cuts
Pfizer is making strides in the rapidly growing weight management market. The company is committed to developing a franchise around obesity and cachexia treatments. This focus aligns with the ...
Forbes1mon
What's Happening With Pfizer Stock?
Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period. PFE stock was trading at $47 ...
The Washington Post25d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Albert Bourla, who four years ago led Pfizer through its scientific and financial triumph during the covid-19 pandemic, is suddenly facing a new challenge from a large shareholder frustrated over ...